（股份代號：6996） 自願公告 希維奧®在香港獲批用於治療多發性骨髓瘤 及瀰漫大B細胞淋巴瘤兩種新增適應症 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Antengene Corporation Limited 德琪醫藥有限公司 （於開曼群島註冊成立的有限公司） 德琪醫藥有限公司（簡稱「德琪醫藥」，香港交易所股票代碼：6996.HK）是一家以 研發為驅動的全球商業化階段生物科技公司，專注於開發治療具有未獲滿足的大 量醫療需求的疾病的同類首款和同類最優療法。其產品管線涵蓋臨床前階段到商 業化階段並包括多個內部開發項目，當中包括ATG-022（CLDN18.2抗體藥物偶聯 物）、ATG-037（口服CD73抑制劑）、ATG-101（PD-L1 × 4-1BB雙特異性抗體）、 ATG-031（靶向CD24巨噬細胞激活劑）及ATG-042（口服PRMT5-MTA抑制劑）。 德琪醫藥亦開發了AnTenGager™，其為專有的T細胞銜接器2.0平台，具有「 ...

Core Viewpoint - 德琪医药 is showcasing its strength as an innovative biopharmaceutical company with a focus on developing breakthrough therapies to improve patient survival quality globally, particularly in oncology and autoimmune diseases [1]. Group 1: Company Performance - 德琪医药's stock price has surged over 347.69% year-to-date as of June 30, 2025, reflecting strong market performance driven by its innovative drug pipeline [1][4]. - The company has a robust research and development pipeline, including a second-generation TCE platform and late-stage global assets, which are expected to provide long-term growth momentum [5]. Group 2: Innovative Technology - The AnTenGager™ platform, a new second-generation "2+1" TCE technology, enhances safety and efficacy through spatial steric shielding, reducing the risk of cytokine release syndrome (CRS) and expanding targeting capabilities [8]. - The platform's advantages include improved safety, expanded targeting ability for low-expressing antigens, broad applicability across various cancers and autoimmune diseases, and a strong patent barrier due to unique antibody sequences [8][9]. Group 3: Key Products - ATG-022 (Claudin 18.2 ADC) is advancing in clinical trials, with a peak sales potential estimated at $5 billion, demonstrating significant efficacy in both high and low expression patient populations [10][14]. - ATG-037, an oral CD73 small molecule, is set to enter Phase II clinical trials, showing promising results in combination with KEYTRUDA® for melanoma patients resistant to immune checkpoint inhibitors [15]. Group 4: Strategic Initiatives - 德琪医药 has initiated an open strategy for the AnTenGager™ platform, focusing on technology licensing, joint development, and product authorization to maximize platform value [9]. - The company is actively pursuing a dual model of business development and licensing cooperation to sustain growth momentum in the future [9].